NCT05936138

A Study of LY3502970 in Participants With Normal and Impaired Renal Function

A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to assess the amount of study drug (LY3502970) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to participants with normal renal function. The safety and tolerability of LY3502970 will also be evaluated in these participants. The study will last up to 6 weeks including screening period.

Conditions

• Renal Insufficiency
• Healthy

Interventions

Type	Name	Description
DRUG	LY3502970	Administered orally.

Timeline

• Start date: 2023-07-13
• Primary completion: 2024-04-11
• Completion: 2024-04-11
• First posted: 2023-07-07
• Last updated: 2024-04-23

Locations

4 sites across 1 country: United States

Regulatory

• FDA-regulated drug study